Drug details

Gazyva (obinutuzumab injection)

type of Antineoplastics, Anti-CD20 Monoclonal Antibodies

Gazyva (obinutuzumab) Injection is a monoclonal antibody used in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• fever,
• chills,
• headache,
• cough,
• flushing,
• high blood pressure (hypertension),
• low white blood cell counts,
• infusion reactions,
• low platelet counts, and
• low red blood cell counts

The following drugs are related to Gazyva, either as a replacement or used together:

• Aliqopa (copanlisib for injection, for intravenous use)
• Belrapzo (bendamustine hydrochloride injection)
• Vivimusta (bendamustine hydrochloride injection)
• Breyanzi (lisocabtagene maraleucel suspension for intravenous infusion)
• Cerubidine (daunorubicin)
• Leustatin (cladribine injection for intravenous infusion only)
• Idamycin (idarubicin)
• Zynlonta (loncastuximab tesirine-lpyl for injection)
• Turalio (pexidartinib capsules)
• Truxima (rituximab-abbs injection)
• Tazverik (tazemetostat tablets)
• Vumon (teniposide)
• Vesanoid (tretinoin)
• Ukoniq (umbralisib tablets)
• Venclexta (venetoclax tablets)